Middle East Downstream Week

In a trading update, the group said it has continued to develop and license its "body area networks" for end-to-end healthcare systems. The Sensium is an ultra low power technology platform that provides unobtrusive, continuous, wireless monitoring of vital signs that enables the analysis and interpretation of physiological data.

The company said the first trials at St. Mary's Hospital were successfully completed in February and further trials of the complete end-to-end system are expected to start in fourth quarter. This will clear the way for FDA and CE regulatory filing during 2011, with the first royalty revenues expected in the latter part of that year, the company added.

Toumaz expects to publish its interim results in mid September.

TMZ.L shares closed Tuesday's regular trading at 5.50 pence on the LSE.

Source: Rttnews.com, June 30th, 2010